104 related articles for article (PubMed ID: 38713636)
1. The Human Intermediate Prolactin Receptor I-tail Contributes Breast Oncogenesis by Targeting Ras/MAPK Pathway.
Shen S; Radhakrishnan SK; Harrell JC; Puchalapalli M; Koblinski J; Clevenger C
Endocrinology; 2024 Apr; 165(6):. PubMed ID: 38713636
[TBL] [Abstract][Full Text] [Related]
2. The human intermediate prolactin receptor is a mammary proto-oncogene.
Grible JM; Zot P; Olex AL; Hedrick SE; Harrell JC; Woock AE; Idowu MO; Clevenger CV
NPJ Breast Cancer; 2021 Mar; 7(1):37. PubMed ID: 33772010
[TBL] [Abstract][Full Text] [Related]
3. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
4. Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
Plotnikov A; Varghese B; Tran TH; Liu C; Rui H; Fuchs SY
Cancer Res; 2009 Apr; 69(7):3165-72. PubMed ID: 19276348
[TBL] [Abstract][Full Text] [Related]
5. The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.
Fiorillo AA; Medler TR; Feeney YB; Wetz SM; Tommerdahl KL; Clevenger CV
Am J Pathol; 2013 Jan; 182(1):217-33. PubMed ID: 23159947
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.
Sakamoto K; Triplett AA; Schuler LA; Wagner KU
Oncogene; 2010 Sep; 29(39):5359-69. PubMed ID: 20639901
[TBL] [Abstract][Full Text] [Related]
7. Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2016 Oct; 7(40):65602-65613. PubMed ID: 27564112
[TBL] [Abstract][Full Text] [Related]
8. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
9. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells.
Aksamitiene E; Achanta S; Kolch W; Kholodenko BN; Hoek JB; Kiyatkin A
Cell Signal; 2011 Nov; 23(11):1794-805. PubMed ID: 21726627
[TBL] [Abstract][Full Text] [Related]
10. TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.
Oberst MD; Beberman SJ; Zhao L; Yin JJ; Ward Y; Kelly K
BMC Cancer; 2008 Jul; 8():189. PubMed ID: 18597688
[TBL] [Abstract][Full Text] [Related]
11. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
[TBL] [Abstract][Full Text] [Related]
12. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
13. Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity.
Zhao D; Ma G; Zhang X; He Y; Li M; Han X; Fu L; Dong XY; Nagy T; Zhao Q; Fu L; Dong JT
J Biol Chem; 2016 Jun; 291(24):12809-12820. PubMed ID: 27129249
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
15. Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor.
Plotnikov A; Li Y; Tran TH; Tang W; Palazzo JP; Rui H; Fuchs SY
Cancer Res; 2008 Mar; 68(5):1354-61. PubMed ID: 18316598
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of microRNAs expressed in human breast cancer T-47D cells in response to prolactin treatment by Solexa deep-sequencing technology.
Wei Q; He W; Yao J; Guo L; Lu Y; Cao X
Biochem Biophys Res Commun; 2013 Mar; 432(3):480-7. PubMed ID: 23410749
[TBL] [Abstract][Full Text] [Related]
17. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling.
Shrestha Y; Schafer EJ; Boehm JS; Thomas SR; He F; Du J; Wang S; Barretina J; Weir BA; Zhao JJ; Polyak K; Golub TR; Beroukhim R; Hahn WC
Oncogene; 2012 Jul; 31(29):3397-408. PubMed ID: 22105362
[TBL] [Abstract][Full Text] [Related]
18. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
19. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
20. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
Kavarthapu R; Dufau ML
Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
